1.25 USD
-0.01 (-0.79%)
Taking everything into account, AIM scores 1 out of 10 in our fundamental rating. AIM was compared to 525 industry peers in the Biotechnology industry. AIM has a bad profitability rating. Also its financial health evaluation is rather negative. AIM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year AIM has reported negative net income.
- In the past year AIM has reported a negative cash flow from operations.
- AIM had negative earnings in each of the past 5 years.
- AIM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- AIM has a worse Return On Assets (-391.52%) than 93.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -391.52% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AIM has a better Gross Margin (71.07%) than 81.90% of its industry peers.
- The Profit Margin and Operating Margin are not available for AIM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AIM has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, AIM has less shares outstanding
- Compared to 1 year ago, AIM has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -162.69, we must say that AIM is in the distress zone and has some risk of bankruptcy.
- AIM's Altman-Z score of -162.69 is on the low side compared to the rest of the industry. AIM is outperformed by 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -162.69 |
ROIC/WACCN/A
WACC8.43%
2.3 Liquidity
- AIM has a Current Ratio of 0.10. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
- AIM has a Current ratio of 0.10. This is amonst the worse of the industry: AIM underperforms 94.10% of its industry peers.
- AIM has a Quick Ratio of 0.10. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.10, AIM is not doing good in the industry: 94.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 58.18% over the past year.
- The Revenue for AIM has decreased by -15.84% in the past year. This is quite bad
- AIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.96% yearly.
EPS 1Y (TTM)58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.49%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%
3.2 Future
- Based on estimates for the next years, AIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.08% on average per year.
- AIM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y77.28%
EPS Next 2Y37.74%
EPS Next 3Y24.93%
EPS Next 5Y15.08%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y-14.87%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year AIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AIM's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.74%
EPS Next 3Y24.93%
5. Dividend
5.1 Amount
- No dividends for AIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AIM IMMUNOTECH INC / AIM FAQ
What is the ChartMill fundamental rating of AIM IMMUNOTECH INC (AIM) stock?
ChartMill assigns a fundamental rating of 1 / 10 to AIM.
What is the valuation status for AIM stock?
ChartMill assigns a valuation rating of 1 / 10 to AIM IMMUNOTECH INC (AIM). This can be considered as Overvalued.
Can you provide the profitability details for AIM IMMUNOTECH INC?
AIM IMMUNOTECH INC (AIM) has a profitability rating of 1 / 10.
What is the expected EPS growth for AIM IMMUNOTECH INC (AIM) stock?
The Earnings per Share (EPS) of AIM IMMUNOTECH INC (AIM) is expected to grow by 77.28% in the next year.